Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| MetforminNCT00814372 | Gilead SciencesPHASE2 | TERMINATED MBX-102 did not meet the target efficacy profile of HbA1c change. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| ActosNCT00814372 | Gilead SciencesPHASE2 | TERMINATED MBX-102 did not meet the target efficacy profile of HbA1c change. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| MBX-102NCT00814372 | Gilead SciencesPHASE2 | TERMINATED MBX-102 did not meet the target efficacy profile of HbA1c change. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Cellgram-DCNCT04614051 | Pharmicell Co., Ltd.PHASE1 | TERMINATED Difficulties in patient recruitment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Intravenous lidocaineNCT07770581 | Ann & Robert H Lurie Children's Hospital of ChicagoNA | TERMINATED PI left institution and study activity was not continued (enrollment not complete) | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| MavacamtenNCT05582395 | Bristol-Myers SquibbPHASE3 | TERMINATED Trial terminated because of lack of efficacy in the short term acute phase | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| standard of care second-line chemotherapy (FOLFIRI)NCT07061080 | Grupo Espanol de Tumores NeuroendocrinosPHASE2 | TERMINATED AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| TarlatamabNCT07061080 | Grupo Espanol de Tumores NeuroendocrinosPHASE2 | TERMINATED AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| GSK3915393NCT06317285 | GlaxoSmithKlinePHASE2 | TERMINATED The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| dose dense MVAC with pegylated GCSFNCT04047693 | Pusan National University Yangsan HospitalPHASE2 | TERMINATED Poor accrual due to increased use of alternative neoadjuvant treatment options. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| RVU120NCT05052255 | Ryvu Therapeutics SAPHASE1, PHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| JMT103NCT04198480 | Shanghai JMT-Bio Inc.PHASE1, PHASE2 | TERMINATED Due to a change in the company's research strategy | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| RVU120(SEL120)NCT04021368 | Ryvu Therapeutics SAPHASE1 | TERMINATED RPD2 has been identified | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| BulevirtideNCT05718700 | Gilead SciencesPhase unknown | TERMINATED Sponsor decision, no safety concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Autologous total tumor mRNA loaded DOTAP liposome vaccineNCT05264974 | University of FloridaPHASE1 | SUSPENDED seeking additional funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Background Regimen (BR)NCT02354014 | Janssen Research & Development, LLCPHASE2 | SUSPENDED As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Bedaquiline (TMC207)NCT02354014 | Janssen Research & Development, LLCPHASE2 | SUSPENDED As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| paracetamolNCT02094807 | Sahlgrenska University HospitalNA | WITHDRAWN Slow inclusion rate. Awaiting results from NCT02132416. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| opioidsNCT02094807 | Sahlgrenska University HospitalNA | WITHDRAWN Slow inclusion rate. Awaiting results from NCT02132416. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| NSAIDNCT02094807 | Sahlgrenska University HospitalNA | WITHDRAWN Slow inclusion rate. Awaiting results from NCT02132416. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Bupivacaine onlyNCT05823363 | Jefferson DrapkinPHASE4 | WITHDRAWN PI left institution | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Exparel with BubivacaineNCT05823363 | Jefferson DrapkinPHASE4 | WITHDRAWN PI left institution | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| OxygenNCT06498908 | Jefferson DrapkinPHASE3 | WITHDRAWN Withdrawn due to study staff leaving institution | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Nitrous oxideNCT06498908 | Jefferson DrapkinPHASE3 | WITHDRAWN Withdrawn due to study staff leaving institution | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-17 |
| Vaginal Cream with ApplicatorNCT04807894 | Jefferson DrapkinPHASE4 | TERMINATED High rates of loss to follow up | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-17 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |